Atlas Trials

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

Clinical trial NCT05207865 · COMPLETED

Trial details

NCT number
NCT05207865
Sponsor
Pfizer
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
MigraineEpisodic MigrainePhonophobiaPhotophobia
Start date
2022-03-15
Primary completion
2024-07-02
Enrollment
441

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.